Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

H Ghesquières; G Cartron; JF Seymour; MH Delfau-Larue; F Offner; P Soubeyran; A Perrot; P Brice; R Bouabdallah; A Sonet; J Dupuis; O Casasnovas; JV Catalano; A Delmer; F Jardin; A Verney; P Dartigues; G Salles

Journal article

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

H Ghesquières, G Cartron, JF Seymour, MH Delfau-Larue, F Offner, P Soubeyran, A Perrot, P Brice, R Bouabdallah, A Sonet, J Dupuis, O Casasnovas, JV Catalano, A Delmer, F Jardin, A Verney, P Dartigues, G Salles

Blood | Published : 2012

DOI: 10.1182/blood-2012-05-431825

Abstract

In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab mai..

View full abstract